Tajikistan Medical Device Regulation 2026: Nine Cases Exempt from State Registration

1. Key takeaways

The law of Tajikistan expressly enumerates nine categories of situations that do not require state registration. Article 17(4) of Law No. 1893 provides that state registration is not carried out for the following: medicines prepared in pharmacies upon the application of healthcare institutions; pharmaceutical substances produced in accordance with the good manufacturing practice requirements of the World Health Organization; medicines and pharmaceutical substances produced within Tajikistan solely for export; parapharmaceuticals without therapeutic properties; excipients; domestically produced pharmacopoeial plant raw materials; samples of medicines and medical goods intended for exhibitions and without the right of further sale; medical goods manufactured solely on individual patient orders for personal use; and samples of medicines and medical goods intended for preclinical and clinical research. GRZAN notes: this list is an exhaustive enumeration; anything outside the list requires registration.

2. Legal basis

3. Expert insights

Insight 1: Items 7 and 9 are the most valuable for device companies, but both carry strict conduct limits. Item 7 exempts samples intended for exhibitions and without the right of further sale — the key words are without the right of further sale. This means that gifting after the exhibition, resale, or leaving samples with local medical institutions all void the exemption. Item 9 exempts samples intended for preclinical and clinical research, which forms a paired combination of registration exemption and import exemption with Article 26(8), item 4 (import and export for preclinical and clinical trials) — this is critical: if registration is exempted, the import must be exempted too, and both stages must match up.

Insight 2: Item 8, manufacture on individual patient orders, is directly relevant to custom-made devices. The exemption covers medical goods manufactured solely on individual patient orders for personal use, which covers prosthetics, orthoses, custom dental restorations and other personalized products. But the provision contains three qualifiers: solely, individual orders, and personal use. The judgment of GRZAN is that standardized devices produced in batches, even when adjusted to individual patient parameters, do not fall under this item; only products truly manufactured as single pieces against a single patient order may apply.

Insight 3: Exemption from registration does not mean exemption from other obligations. Article 17(4) resolves only the single question of whether registration is required. Samples entering Tajikistan must still comply with the import and export rules of Article 26: exhibition samples must satisfy Article 26(8), item 6 (import and export for display at exhibitions, trade fairs and conferences, without the right to sell), and research samples must satisfy items 4 and 8 of that paragraph. Moreover, Article 21(1), item 1 still lists failure to register in Tajikistan as a ground for withdrawal from circulation — showing that exemption situations and the withdrawal provision must be precisely aligned; once the boundary of the exemption is crossed, the consequence is withdrawal from circulation.

Insight 4: Item 3, production within the territory solely for export, is a supporting clause of the domestic substitution policy. The exemption targets products produced in Tajikistan exclusively for export. Read together with Article 4, item 5, state support for the development of domestic production of medicines and medical goods, a state policy principle, it is clear the legislator has left open a channel for a local manufacturing, export-oriented industrial model. The implication for Chinese manufacturers is that if a plant is established in Tajikistan with that country as an export base, the portion of products destined for export does not require Tajik state registration.

4. Practical recommendations

1. Build a dual-exemption-list checklist. When handling exhibition and research samples, GRZAN checks both Article 17(4) (registration exemption) and Article 26(8) (import exemption) to ensure each stage has its own independent basis — neither can substitute for the other.
2. Keep full records for exhibition samples. For item 7, maintain an inbound and outbound ledger and final disposition records (re-export or destruction) for exhibition samples, to demonstrate the absence of further sale. Gifting samples away or retaining them locally voids the exemption directly.
3. Archive custom-made devices order by order. For item 8, retain the patient order, fitting records and user information for each custom product, in preparation for possible inspections.
4. Design a separate export pathway for companies with plants in Tajikistan. Where item 3 applies, clearly mark the products as for export only in production and customs documents, and retain export customs declarations as evidence of the exemption.

5. Verification checklist

• □ Compared item by item against the nine registration exemption situations of Article 17(4)
• □ Confirmed each exemption situation also has an import exemption basis under Article 26(8)
• □ Established an inbound and outbound ledger and final disposition records for exhibition samples (demonstrating no right of further sale)
• □ Retained patient orders, fitting records and user information for each custom-made device
• □ Marked products as for export only in production and customs documents (where item 3 applies)
• □ Confirmed that products crossing the exemption boundary fall under withdrawal from circulation under Article 21(1), item 1
• □ Confirmed the nine-item list is exhaustive and everything outside it requires registration

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com